blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2838531

EP2838531 - INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  28.07.2017
Database last updated on 26.03.2026
Most recent event   Tooltip19.06.2020Lapse of the patent in a contracting state
New state(s): HR		published on 22.07.2020  [2020/30]
Applicant(s)For all designated states
Annji Pharmaceutical Co., Ltd.
5F., No.25-1, Sec.4
Ren-ai Rd., Da-an Dist.
Taipei City 10685, Taiwan / CN
[2016/30]
Former [2015/09]For all designated states
Annji Pharmaceutical Co. Ltd.
Rm 2 12FL
No. 1 Guangfu S. Rd.
Sungshan Chiu
Taipei
Taiwan 105 / US
Inventor(s)01 / CHERN, Ji-Wang
RM.1343
No.1 Sec. 1
Ren'ai Rd.
Zhongzheng Dist.
Taipei City, Taiwan, R.O.C., 100 / TW
02 / JAGTAP, Ajit Dhananjay
RM.1343
No.1 Sec. 1
Ren'ai Rd.
Zhongzheng Dist.
Taipei City, Taiwan, R.O.C., 100 / TW
03 / WANG, Hsiao-Chun
Rm.1343
No.1, Sec.1
Ren'ai Rd.
Zhongzheng Dist.
Taipei City, Taiwan, R.O.C., 100 / TW
04 / CHEN, Grace Shiahuy
Rm.1343
No.1, Sec. 1
Ren'ai Rd.
Zhongzheng Dist.
Taipei City 100 Taiwan R.O.C. / TW
 [2016/38]
Former [2015/09]01 / CHERN, Ji-Wang
RM.1343
No.1 Sec. 1
Ren'ai Rd.
Zhongzheng Dist.
Taipei City 100 Taiwan R.O.C. / TW
02 / JAGTAP, Ajit Dhananjay
RM.1343
No.1
Sec. 1
Ren'ai Rd., Zhongzheng Dist.
Taipei City 100 Taiwan R.O.C. / TW
03 / WANG, Hsiao-Chun
Rm.1343
No.1
Sec. 1
Ren'ai Rd., Zhongzheng Dist.
Taipei City 100 Taiwan R.O.C. / TW
04 / CHEN, Grace Shiahuy
Rm.1343
No.1
Sec. 1
Ren'ai Rd., Zhongzheng Dist.
Taipei City 100 Taiwan R.O.C. / TW
Representative(s)Gill, Siân Victoria, et al
Venner Shipley LLP
200 Aldersgate
London EC1A 4HD / GB
[2015/09]
Application number, filing date13777764.503.04.2013
[2016/38]
WO2013US35177
Priority number, dateUS201261635931P20.04.2012         Original published format: US 201261635931 P
[2015/09]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013158373
Date:24.10.2013
Language:EN
[2013/43]
Type: A1 Application with search report 
No.:EP2838531
Date:25.02.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 24.10.2013 takes the place of the publication of the European patent application.
[2015/09]
Type: B1 Patent specification 
No.:EP2838531
Date:21.09.2016
Language:EN
[2016/38]
Search report(s)International search report - published on:US24.10.2013
(Supplementary) European search report - dispatched on:EP18.11.2015
ClassificationIPC:A61K31/522, A61P35/00, C07D401/14, C07D401/06, C07D403/06, C07D403/14, C07D405/06, C07D409/06, C07D473/32
[2015/51]
CPC:
C07D209/34 (EP,CN,US); C07D401/14 (EP,CN,RU,US); A61K31/522 (RU,US);
A61K38/45 (US); A61P31/20 (EP); A61P31/22 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P43/00 (EP);
C07D209/00 (EP,CN,US); C07D401/06 (EP,CN,US); C07D403/06 (EP,CN,RU,US);
C07D403/14 (EP,CN,RU,US); C07D405/06 (EP,CN,RU,US); C07D409/06 (EP,CN,US);
C07D473/32 (US); A61K31/404 (RU); C07D473/18 (RU) (-)
Former IPC [2015/09]A61K31/404
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/09]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:INDOLIN-2-ON-DERIVATE ALS PROTEINKINASEINHIBITOREN[2015/09]
English:INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS[2015/09]
French:DÉRIVÉS D'INDOLIN-2-ONE À TITRE D'INHIBITEURS DE PROTÉINES KINASES[2015/09]
Entry into regional phase30.09.2014National basic fee paid 
30.09.2014Search fee paid 
30.09.2014Designation fee(s) paid 
30.09.2014Examination fee paid 
Examination procedure30.09.2014Examination requested  [2015/09]
03.12.2015Amendment by applicant (claims and/or description)
25.02.2016Despatch of a communication from the examining division (Time limit: M04)
22.03.2016Reply to a communication from the examining division
21.04.2016Communication of intention to grant the patent
08.08.2016Fee for grant paid
08.08.2016Fee for publishing/printing paid
08.08.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  25.02.2016
Opposition(s)22.06.2017No opposition filed within time limit [2017/35]
Fees paidRenewal fee
27.04.2015Renewal fee patent year 03
27.04.2016Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU03.04.2013
AL21.09.2016
AT21.09.2016
BE21.09.2016
CY21.09.2016
CZ21.09.2016
DK21.09.2016
EE21.09.2016
FI21.09.2016
HR21.09.2016
LT21.09.2016
LV21.09.2016
MC21.09.2016
MK21.09.2016
NL21.09.2016
PL21.09.2016
RO21.09.2016
RS21.09.2016
SE21.09.2016
SI21.09.2016
SK21.09.2016
SM21.09.2016
TR21.09.2016
BG21.12.2016
NO21.12.2016
GR22.12.2016
IS21.01.2017
PT23.01.2017
IE03.04.2017
LU03.04.2017
MT03.04.2017
CH30.04.2017
LI30.04.2017
[2020/30]
Former [2020/15]HU03.04.2013
AL21.09.2016
AT21.09.2016
BE21.09.2016
CY21.09.2016
CZ21.09.2016
DK21.09.2016
EE21.09.2016
FI21.09.2016
LT21.09.2016
LV21.09.2016
MC21.09.2016
MK21.09.2016
NL21.09.2016
PL21.09.2016
RO21.09.2016
RS21.09.2016
SE21.09.2016
SI21.09.2016
SK21.09.2016
SM21.09.2016
TR21.09.2016
BG21.12.2016
NO21.12.2016
GR22.12.2016
IS21.01.2017
PT23.01.2017
IE03.04.2017
LU03.04.2017
MT03.04.2017
CH30.04.2017
LI30.04.2017
Former [2019/51]HU03.04.2013
AL21.09.2016
AT21.09.2016
BE21.09.2016
CY21.09.2016
CZ21.09.2016
DK21.09.2016
EE21.09.2016
FI21.09.2016
LT21.09.2016
LV21.09.2016
MC21.09.2016
MK21.09.2016
NL21.09.2016
PL21.09.2016
RO21.09.2016
RS21.09.2016
SE21.09.2016
SI21.09.2016
SK21.09.2016
SM21.09.2016
BG21.12.2016
NO21.12.2016
GR22.12.2016
IS21.01.2017
PT23.01.2017
IE03.04.2017
LU03.04.2017
MT03.04.2017
CH30.04.2017
LI30.04.2017
Former [2019/47]HU03.04.2013
AL21.09.2016
AT21.09.2016
BE21.09.2016
CY21.09.2016
CZ21.09.2016
DK21.09.2016
EE21.09.2016
FI21.09.2016
LT21.09.2016
LV21.09.2016
MC21.09.2016
NL21.09.2016
PL21.09.2016
RO21.09.2016
RS21.09.2016
SE21.09.2016
SI21.09.2016
SK21.09.2016
SM21.09.2016
BG21.12.2016
NO21.12.2016
GR22.12.2016
IS21.01.2017
PT23.01.2017
IE03.04.2017
LU03.04.2017
MT03.04.2017
CH30.04.2017
LI30.04.2017
Former [2019/31]HU03.04.2013
AL21.09.2016
AT21.09.2016
BE21.09.2016
CZ21.09.2016
DK21.09.2016
EE21.09.2016
FI21.09.2016
LT21.09.2016
LV21.09.2016
MC21.09.2016
NL21.09.2016
PL21.09.2016
RO21.09.2016
RS21.09.2016
SE21.09.2016
SI21.09.2016
SK21.09.2016
SM21.09.2016
BG21.12.2016
NO21.12.2016
GR22.12.2016
IS21.01.2017
PT23.01.2017
IE03.04.2017
LU03.04.2017
MT03.04.2017
CH30.04.2017
LI30.04.2017
Former [2018/47]AL21.09.2016
AT21.09.2016
BE21.09.2016
CZ21.09.2016
DK21.09.2016
EE21.09.2016
FI21.09.2016
LT21.09.2016
LV21.09.2016
MC21.09.2016
NL21.09.2016
PL21.09.2016
RO21.09.2016
RS21.09.2016
SE21.09.2016
SI21.09.2016
SK21.09.2016
SM21.09.2016
BG21.12.2016
NO21.12.2016
GR22.12.2016
IS21.01.2017
PT23.01.2017
IE03.04.2017
LU03.04.2017
MT03.04.2017
CH30.04.2017
LI30.04.2017
Former [2018/43]AT21.09.2016
BE21.09.2016
CZ21.09.2016
DK21.09.2016
EE21.09.2016
FI21.09.2016
LT21.09.2016
LV21.09.2016
MC21.09.2016
NL21.09.2016
PL21.09.2016
RO21.09.2016
RS21.09.2016
SE21.09.2016
SI21.09.2016
SK21.09.2016
SM21.09.2016
BG21.12.2016
NO21.12.2016
GR22.12.2016
IS21.01.2017
PT23.01.2017
IE03.04.2017
LU03.04.2017
MT03.04.2017
CH30.04.2017
LI30.04.2017
Former [2018/14]AT21.09.2016
BE21.09.2016
CZ21.09.2016
DK21.09.2016
EE21.09.2016
FI21.09.2016
LT21.09.2016
LV21.09.2016
MC21.09.2016
NL21.09.2016
PL21.09.2016
RO21.09.2016
RS21.09.2016
SE21.09.2016
SI21.09.2016
SK21.09.2016
SM21.09.2016
BG21.12.2016
NO21.12.2016
GR22.12.2016
IS21.01.2017
PT23.01.2017
LU03.04.2017
CH30.04.2017
LI30.04.2017
Former [2018/06]AT21.09.2016
BE21.09.2016
CZ21.09.2016
DK21.09.2016
EE21.09.2016
FI21.09.2016
LT21.09.2016
LV21.09.2016
MC21.09.2016
NL21.09.2016
PL21.09.2016
RO21.09.2016
RS21.09.2016
SE21.09.2016
SI21.09.2016
SK21.09.2016
SM21.09.2016
BG21.12.2016
NO21.12.2016
GR22.12.2016
IS21.01.2017
PT23.01.2017
Former [2017/52]AT21.09.2016
BE21.09.2016
CZ21.09.2016
DK21.09.2016
EE21.09.2016
FI21.09.2016
LT21.09.2016
LV21.09.2016
NL21.09.2016
PL21.09.2016
RO21.09.2016
RS21.09.2016
SE21.09.2016
SI21.09.2016
SK21.09.2016
SM21.09.2016
BG21.12.2016
NO21.12.2016
GR22.12.2016
IS21.01.2017
PT23.01.2017
Former [2017/34]AT21.09.2016
BE21.09.2016
CZ21.09.2016
DK21.09.2016
EE21.09.2016
FI21.09.2016
LT21.09.2016
LV21.09.2016
NL21.09.2016
PL21.09.2016
RO21.09.2016
RS21.09.2016
SE21.09.2016
SK21.09.2016
SM21.09.2016
BG21.12.2016
NO21.12.2016
GR22.12.2016
IS21.01.2017
PT23.01.2017
Former [2017/32]AT21.09.2016
BE21.09.2016
CZ21.09.2016
EE21.09.2016
FI21.09.2016
LT21.09.2016
LV21.09.2016
NL21.09.2016
PL21.09.2016
RO21.09.2016
RS21.09.2016
SE21.09.2016
SK21.09.2016
SM21.09.2016
BG21.12.2016
NO21.12.2016
GR22.12.2016
IS21.01.2017
PT23.01.2017
Former [2017/13]FI21.09.2016
LT21.09.2016
LV21.09.2016
NL21.09.2016
RS21.09.2016
SE21.09.2016
NO21.12.2016
GR22.12.2016
Former [2017/11]FI21.09.2016
LT21.09.2016
RS21.09.2016
SE21.09.2016
NO21.12.2016
GR22.12.2016
Former [2017/10]FI21.09.2016
LT21.09.2016
RS21.09.2016
SE21.09.2016
NO21.12.2016
Former [2017/09]FI21.09.2016
LT21.09.2016
NO21.12.2016
Former [2017/07]LT21.09.2016
Documents cited:Search[A]   KHANWELKAR R R ET AL: "Synthesis and structure-activity relationship of 6-arylureido-3-pyrrol-2-ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 18, no. 13, 1 July 2010 (2010-07-01), pages 4674 - 4686, XP027083655, ISSN: 0968-0896, [retrieved on 20100512] [A] 1-15 * compound 35 * * tables 2 and 3 *
by applicant  KHANWELKAR ET AL.: "synthesis and structure-activity relationship of 6-arylureido-3-pyrrol-2-ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 18, no. 13, 2010, pages 4674 - 4686
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.